Although further research is necessary to more extensively delineate the cellular effects of 17-aminogeldanamycin, our study provides molecular evidence that this HSP90 inhibitor can be used for the simultaneous diminution of IL-8 and VEGF levels in an extracellular milieu to reach substantial anti-melanoma effects. Here, VEGFA is linked to melanoma.